Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (82829)	2/14/2000 1:41:00 PM
From: lizard lick	Respond to of 120523

FARO is waking up sector news out today and this one has been beaten down for a long time ADVISORY/US Carmakers Push Demand for Robotics (Business Wire 02/14 13:00:15) Business Editors/Automotive Writers ADVISORY... --(BUSINESS WIRE)--Feb. 14, 2000-- TOPIC: Orders for industrial robots surged 20 percent in 1999, pushed largely by American automakers, the Financial Times reported. According to the United Nations Economic Commission and the International Federation of Robotics, American automakers ordered 60 percent more robots in 1999. The surge in robot use in integrated manufacturing systems follows a relative drop in robot prices. EXPERTS: ExpertSource can offer several highly qualified experts to comment on this story: A. Galip Ulsoy is a professor at the University of Michigan Department of Mechanical Engineering and Applied Mechanics. He is an expert on control of mechanical manufacturing systems, including robotics, in the automotive industry. Shraga Shoval is a professor at Technion in Israel. He is an expert on analysis of robot motion performance and integration of robots in manufacturing systems. Prabhat Hajela is a professor of Aeronautical Engineering & Mechanics at Rensselaer Polytechnic Institute and is an expert on automotive design and structural systems. -0- ExpertSource cannot guarantee the immediate availability of these experts or their familiarity with this specific issue. ExpertSource, a collaboration of Business Wire and The Round Table Group, provides academic and industry experts to the media at no charge. Journalists are encouraged to submit queries to ExpertSource when seeking experts on specific subjects. An online registration form is available at businesswire.com. Business Wire's Media Resource Center provides working journalists many free media services. Please visit the BW Media Resource Center at (www.businesswire.com/media) for more information. --30--jla/cgo* CONTACT: Business Wire, Chicago Christina George, 312/573-0018 christinag@bizwire.com or Business Wire, New York Neil Hershberg, 212/752-9600, ext. 235 neilh@bizwire.com KEYWORD: NEW YORK MICHIGAN INDUSTRY KEYWORD: AUTOMOTIVE ADVISORY Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com S.BW

To: Jenna who wrote (82829)	2/14/2000 4:50:00 PM
From: Junkyardawg	Respond to of 120523

Jenna Its me again;-) ADI has its earnings on Wed I invite you to read this news that came out today regarding ADI's earnings. LOS ANGELES (CBS.MW) -- Investors are getting excited about Analog Devices' (ADI: news, msgs) first-quarter earnings release. Hambrecht & Qusit's analyst Lucas Ward couldn't agree more with the positive sentiment. He believes the company could "significantly" beat his estimate of 43 cents a share. "We believe the analog sector continues to experience unseasonal strong demand, due to secular strength in communications and a resurgence in demand from Asia and the global PC market," said Ward in morning research notes. Analysts polled by First Call currently expect a profit of 45 cents a share, well ahead of the 18 cents recorded in the first-quarter of last year. "We believe that we are well positioned for a very good fiscal 2000," said Ray Stata, chairman, in the company's annual proxy release, "While some of our success can be attributed to a strong semiconductor cycle, we are mostly benefiting from our strong new product developments that are aimed at the fastest growing end markets." The report is slated for Feb. 16, Wednesday, before the market opens. The stock traded up 2 15/16 to 117 9/16.

To: Jenna who wrote (82829)	2/15/2000 1:48:00 PM
From: Jenna	Read Replies (1) \| Respond to of 120523

<<ALERT>> Earnings Play #7 for 17 explodes +15%.. biotech earnings plays: CLPA and IVGN this week's earnings plays movers and MYGN and MEDX which was for the February 7 list and moved up quite a bit since their buy triggers. and SCLN, ADRX PCOP from the 24th of January. CALP from the week of January 31. MOGN was another one that did well only in anticipatory upswing and we're still waiting for a buy trigger to reenter. from the Market Gems Calendar: Stock Pick of the day for January 12, 2000 Another angle is companies such as Invitrogen (Nasdaq:IVGN - news) that provide equipment and supplies to the genomic research market. Invitrogen's stock has surged in recent months, but substantially less than some of the companies just mentioned. Invitrogen sells research tool kits for gene cloning, expression and analysis, as well as other products and services that cater to the blossoming field of genomics research. This company targets the molecular biology and functional genomics markets. Functional genomics refers to the commercial and academic groups working to determine the function of certain genes and apply DNA information to the development of therapeutics and diagnostics. Invitrogen's kits are used at the most basic level of research in genomics studies. These kits help researchers isolate, clone and test genes more efficiently. In this way Invitrogen is a "picks and shovels" play on the genomics gold rush. Instead of prospecting for gold in the hopes of hitting the mother lode, they sell tools to the hordes of researchers and companies that are scrambling to advance medicine and capitalize on recent breakthroughs in DNA research. This company just went public last February at $15 and the stock has surged to $54.50 currently. While it's no longer a cheap entry into the exciting field of genomics, it does offer a way for investors to participate in the blossoming industry without exposure to the huge risks like FDA approval associated with most biotech investments. That's the beauty of a picks and shovels play. -------------------------------------------------------------------------------- Research Analyst with Hambrecht & Quist says on IVGN: On Invitrogen, their fundamental growth rate historically has been high and it's projected to stay there Fundamentals: From February 11 watch list and the Earnings Calendar: 7> SBL - SYMBOL TECHNOLOGIES INC .DPE Price= 73.6 VL/30= 245.2 %Rnge= 78.0 Sto9V= 94.3 W14dV= 76.0 %Hi4 = 100.0 1-Dy = 104.8 50MA = 126.5 21MA = 120.2 SBL another repeat earnings play. SBL also has strong analyst support and looking for $0.34 versus $0.29. Earnings out on February 15.